Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
847.90
Change Change %
-7.60 -0.89%

Updated:20 Nov, 2018, 15:09 PM IST

BSE
849.35
Change Change %
-6.60 -0.77%

Updated:20 Nov, 2018, 15:15 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Barclays
N/A
16-04-2015 Buy 1899.05 2266.00
N/A
Closed Custom
16-04-2016

Barclays maintains overweight on Lupin

Suprax to face generic competition from Aurobindo Pharma. Suprax accounted for around 8 per cent of sales for Lupin. See a negative impact of 2-3 per cent on FY16 EPS estimates due to the launch of generic version of Suprax by Aurobindo Pharma. Maintain Lupin as our global top pick.

Top